Loss of Ventricular Function After Bidirectional Cavopulmonary Connection: Who Is at Risk?

Marie Vincenti1 · M. Yasir Qureshi1,2 · Talha Niaz2 · Drew K. Seisler1 · Timothy J. Nelson1,2 · Frank Cetta1,2

Received: 2 April 2020 / Accepted: 4 August 2020 / Published online: 11 August 2020 © The Author(s) 2020

Abstract
Decline of single ventricle systolic function after bidirectional cavopulmonary connection (BDCPC) is thought to be a transient phenomenon. We analyzed ventricular function after BDCPC according to ventricular morphology and correlated this evolution to long-term prognosis. A review from Mayo Clinic databases was performed. Visually estimated ejection fraction (EF) was reported from pre-BDCPC to pre-Fontan procedure. The last cardiovascular update was collected to assess long-term prognosis. A freedom from major cardiac event survival curve and a risk factor analysis were performed. 92 patients were included; 52 had left ventricle (LV) morphology and 40 had right ventricle (RV) morphology (28/40 had hypoplastic left heart syndrome (HLHS)). There were no significant differences in groups regarding BDCPC procedure or immediate post-operative outcome. EF showed a significant and relevant decrease from baseline to discharge in the HLHS group: 59 ± 4% to 49 ± 7% or −9% (p < 0.01) vs. 58 ± 3% to 54 ± 6% or −4% in the non-HLHS RV group (p = 0.04) and 61 ± 4% to 60 ± 4% or −1% in the LV group (p = 0.14). Long-term recovery was the least in the HLHS group: EF prior to Fontan 54 ± 2% vs. 56 ± 6% and 60 ± 4%, respectively (p < 0.01). With a median follow-up of 8 years post-BDCPC, six patients had Fontan circulation failure, four died, and three had heart transplantation. EF less than 50% at hospital discharge after BDCPC was strongly correlated to these major cardiac events (HR 3.89; 95% Cl 1.04–14.52). Patients with HLHS are at great risk of ventricular dysfunction after BDCPC. This is not a transient phenomenon and contributes to worse prognosis.

Keyword Single ventricle · Bidirectional cavopulmonary connection · Hypoplastic left heart syndrome · Heart failure

Introduction
The bidirectional cavopulmonary connection (BDCPC) has been utilized as an intermediate procedure prior to Fontan for patients with functionally single ventricle (SV) hearts since the 1980s [1]. The BDCPC is usually performed when a child is 3 to 6 months of age. While many studies have assessed risk factors within the “interstage period” between the index procedure (Norwood operation for hypoplastic left heart syndrome (HLHS)) and BDCPC [2–5] or after Fontan [6–8]; few studies have focused on the period between BDCPC and Fontan.

The BDCPC is thought to have the least morbidity and mortality and is generally associated with a short cardiopulmonary bypass time [9]. However, the BDCPC changes preload parameters of the SV and could impact ventricular function [10] thereby impacting candidacy for Fontan operation and long-term outcome [11]. Sustaining good ventricular function is one of the main goals of management of patients with a functionally SV heart [12, 13].

This study aimed to evaluate ventricular function before and after BDCPC according to ventricular morphology using visually estimated ejection fraction. Our hypothesis was that, after BDCPC, ventricular dysfunction was associated with right ventricular (RV) morphology. Our second goal was to evaluate survivorship from major cardiac events after BDCPC and to identify the risk factors for poor long-term prognosis. Our hypothesis was that the post-BDCPC ventricular dysfunction was associated with worse long-term prognosis.
Methods

We conducted an IRB-approved, retrospective study using chart reviews from the Mayo Clinic SV, HLHS, BDCPC, and Fontan databases. All patients consented for the use of medical records. We included all patients with a functionally SV heart who had a BDCPC at Mayo Clinic (Rochester, MN) between 1997 and 2017. All patients included in this study had pre- and post-BDCPC imaging data available to assess the ventricular function. We created two groups according to the SV morphology: Left ventricle (LV) morphology (LV group) and RV morphology (RV group). The RV group was then subdivided into HLHS (HLHS group) and non-HLHS (non-HLHS RV group). Demographic data, surgical management data, laboratory studies, and echocardiography measurements were collected to assess differences between groups. Catheterization measurements were reported pre-BDCPC and pre-Fontan. Volumetric EF obtained during catheterization was calculated using the stroke volume method as follow: EF = (end-diastolic volume (EDV) − end-systolic volume (ESV))/EDV.

Among the echocardiographic data, atrioventricular valve (AV) regurgitation was visually estimated as: 0 = none or trivial, 1 = mild, 2 = moderate and 3 = severe. Aortic arch obstruction was assessed according to mean systolic Doppler gradient in the descending thoracic aorta as: 0 = none (< 5 mmHg), 1 = mild (5–14 mmHg), 2 = moderate (15–24 mmHg), 3 = severe (≥ 25 mmHg).

Ventricular Function Analysis

We used 2D echocardiographic visually estimated ejection fraction (EF) to assess ventricular function. This is a semi-quantitative measurement of systolic ventricle function by an expert sonographer, comparable to biplane auto-EF [14] and magnetic resonance imaging-EF [15] and usable for both ventricle morphologies. Visually estimated EF was evaluated using several orthogonal planes. It was assessed by sequential evaluation at pre-BDCPC (baseline), hospital discharge, 1 to 3 months post-BDCPC, 6 to 12 months post-BDCPC, and immediately prior to Fontan. To isolate the effect of BDCPC on ventricular function, only patients with normal EF at baseline, defined as EF ≥ 50%, were considered for the primary endpoints. The primary endpoints were defined by the mean change in visually estimated EF at hospital discharge and the mean EF evolution over time from BDCPC to Fontan, according to ventricular morphology.

To assess the reliability of our 2D echocardiographic visually estimated EF measurement, one author (MV) performed a second blinded analysis, on a subset of 30 patients randomly selected at each available time-point.

We finally compared EF results obtained by 2D echocardiography (visually estimated EF) and by catheterization (volumetric EF) at pre-BDCPC and pre-Fontan time-points.

Survival Analysis

The most recent cardiovascular clinical update was collected to assess long-term prognosis. Major cardiovascular events included the following: Fontan circulation failure, Fontan or BDCPC takedown, not a candidate for Fontan completion, thromboembolism, protein-losing enteropathy, plastic bronchitis, liver cirrhosis, heart transplantation, or death. A freedom from major cardiac event survival curve was constructed for each group according to ventricle morphology and discharge EF.

Risk Factor Analysis

Evaluation of risk factors for a major cardiac event was performed to investigate long-term prognosis based on the previous results. Factors that were studied included ventricular dysfunction pre-BDCPC, ventricular dysfunction post-BDCPC (hospital discharge), RV morphology, HLHS anatomy, age at BDCPC < 4 months old, extra cardiac disease, BDCPC bypass time > 65 min, and Nakata index pre-BDCPC < 200 mm/m². EF < 50% was defined as ventricular dysfunction. The secondary endpoint was defined by the hazard ratio (HR) for major cardiac event in patients with ventricular dysfunction post-BDCPC adjusted to baseline EF.

Statistical Analysis

Comparative analysis was conducted between the LV group and the entire RV group. To isolate the effect of HLHS morphology, a subgroup analysis was performed dividing the RV group into HLHS group and non-HLHS RV group and another comparative analysis was conducted among the LV group, the HLHS group, and the non-HLHS RV group.

Descriptive statistics included calculations of mean and standard deviations or median and interquartile 1, 3 for continuous variables according to their distribution, counts, and percent for categorical variables. Differences between groups according to descriptive parameters and mean EF changes (primary endpoint) were analyzed using t-test or one-way ANOVA. Repeated-measures analysis using proc mixed in was performed to show differences in mean EF evolution between groups over time.

Inter-reader reliability for 2D echo visually estimated EF measurement was evaluated using intra-class correlation coefficients (ICC) [16]. ICC values less than 0.5, between 0.5 and 0.75, between 0.75 and 0.9, and greater than 0.9
were indicative of poor, moderate, good, and excellent reliability, respectively [17]. Bland–Altman analysis [12], Spearman’s correlation and linear regression were used to compare EF values obtained by 2D echo (visual assessment) and by catheterization (volumetric calculation). Survival models and risk factor analysis were employed using proc phreg SAS. We performed an adjusted survival analysis of time from BDCPC to the major cardiac events previously described.

Analyses were performed using GraphPad Prism version 5.04 (GraphPad software, San Diego, CA) and SAS software version 9.4 (SAS Institute Inc.Cary, NC). A p value < 0.05 was considered statistically significant.

Results

Ninety-two patients met the inclusion criteria in this study. 52 had LV morphology and 40 had RV morphology (28/40 had HLHS and 12/40 had non-HLHS RV). Specific cardiac lesions included HLHS (30%), tricuspid atresia (22%), double outlet right ventricle (12%), pulmonary atresia with intact ventricular septum (10%), double inlet left ventricle (9%), and unbalanced atrioventricular canal (9%).

Table 1 summarizes descriptive data pre-BDCPC. The RV group had a BDCPC at a younger age than the LV group (6.6 ± 4.3 mos. vs 9.7 ± 9.6 mos., respectively, p = 0.045). The HLHS group (5.3 ± 1.4 mos.) was the youngest at time of BDCPC. The Nakata index was significantly smaller in the RV group than in the LV group (184 ± 94 mm/m2 vs. 251 ± 125 mm/m2, respectively, p = 0.003). In the HLHS group, the Nakata index was the lowest (162 ± 84 mm/m²).

Table 2 summarized descriptive data at time of BDCPC. Almost all (92%) patients had BDCPC using cardiopulmonary bypass and 68.5% underwent an additional procedure during BDCPC. No in-hospital complications were reported for 63% of the patients. One patient died before hospital discharge, at 6 days post-operative, due to hemodynamic failure (this patient came to BDCPC with an LV dominant unbalanced AV canal, severe AV valve regurgitation, and ventricular dysfunction). One patient had BDCPC takedown. That patient had HLHS with a small left superior vena cava and an occluded right superior vena cava who needed a systemic-pulmonary artery shunt intra-operatively.

Eleven of 92 patients (16%) had a > Grade 1 AV valve regurgitation pre-BDCPC. Eight of these 11 patients underwent AV valve surgical repair at time of BDCPC. 7 patients still had a > Grade 1 AV valve regurgitation at time of Fontan. In the non-HLHS RV group, AV valve function declined with time: 8% patients had > Grade 1 regurgitation at pre-BDCPC while 27% had > Grade 1 regurgitation prior to Fontan. There was a significant difference between groups in > Grade 1 AV valve regurgitation at pre-Fontan evaluation (5% in LV group, 10% in HLHS group and 27% in non-HLHS RV group, p = 0.04). Five of 92 patients (5%), all with HLHS, had > Grade 1 aortic arch obstruction pre-stage II. Four of these 5 patients had aortic arch enlargement at time of BDCPC. None had > grade 1 aortic arch obstruction at time of Fontan.

Ventricular Function Analysis

Table 3 reports 2D echo visually estimated EF results from the entire cohort. At baseline, EF mean value was significantly lower in the HLHS group vs the non-HLHS RV and LV groups (55 ± 7% vs 58 ± 3% and 61 ± 5%, respectively, p < 0.01). At discharge, there was a significant decrease of mean EF in the HLHS group (55% to 49 ± 7% (− 6%), p < 0.01) and RV non-HLHS group (58 ± 3% to 54 ± 6% (− 4%), p = 0.04) while EF remained stable in the LV group (61 ± 5% to 59% (− 2%), p = 0.19). In the HLHS group, EF did not recover pre-Fontan as compared to the non-HLHS RV and LV groups (53 ± 3% vs 56 ± 6% and 60 ± 4%, p < 0.01).

Table 4 reports 2D echo visually estimated EF results for patients with EF ≥ 50% at baseline. Results were similar, but the decrease from baseline to discharge was larger in the HLHS group: 59 ± 4% to 49 ± 7% in the HLHS group vs. 58 ± 3% to 54 ± 6% in the non-HLHS RV group and 61 ± 4% to 60 ± 4% in the LV group. Therefore, a mean EF decrease of 9% (p < 0.01) vs 4% (p = 0.04) and 1% (p = 0.14), respectively.

Figure 1 represents the evolution over time of 2D echo visually estimated EF for patients with EF ≥ 50% at baseline according to ventricular morphology. There was a significant difference between groups over time, with a more poor evolution in the HLHS group than in the non-HLHS RV and LV groups (p = 0.02).

2D echo visually estimated EF measurement was associated with good inter-reader reliability: ICC = 0.88; 95% CI [0.75–0.95]. The comparison between EF values obtained by 2D echo and catheterization at pre-BDCPC and pre-Fontan time-points also showed a good reliability with a mean error (bias) of 1.3%; 95% CI [− 5%–+ 7%] and a Spearman’s coefficient rho = 0.64, p < 0.0001. We found a linear correlation between those two methods: Y = 0.91 × X + 0.03 (p < 0.0001).

Survival Analysis

The median follow-up was 8 years [4;12] after BDCPC, there was no difference between groups (8 years [3;11] for the LV group and 7 years [4;14] for the RV group, p = 0.36). Thirty-five patients (19 in the LV group and 16 in the RV group) had ≥ 10 years follow-up. Seventy-seven percent of patients underwent Fontan at a median age of
Thirteen major cardiac events occurred, mainly in the RV group (17.5% vs 9.6%, \( p = 0.35 \)). Most patients with a major cardiac event (62%) experienced ventricular

| Characteristics | Total \((N=92)\) | LV group \((N=52)\) | RV group \((N=40)\) | HLHS group \((N=28)\) | Non-HLHS RV group \((N=12)\) | \( p \) value Comparison | \( p \) value Comparison |
|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Demographic data | Age (months) | 8.3 (7.8) | 9.7 (9.6) | 6.6 (4.3) | 5.3 (1.4) | 9.8 (6.9) | \textbf{0.045} | 0.064 |
| Weight (kg) | 7.0 (2.1) | 7.2 (2.3) | 6.8 (1.7) | 6.3 (1.6) | 7.8 (1.4) | | 0.063 | 0.334 |
| Height (cm) | 65.7 (8.2) | 66.4 (8.9) | 64.8 (7.2) | 62.2 (4.1) | 71.1 (8.9) | | \textbf{0.004} | 0.385 |
| BSA \((\text{m}^2)\) | 0.36 (0.07) | 0.37 (0.08) | 0.35 (0.05) | 0.33 (0.04) | 0.40 (0.06) | | \textbf{0.01} | 0.319 |
| Male \(N\) (%) | 50 (54.3) | 29 (55.7) | 21 (52.5) | 12 (42.9) | 9 (75.0) | | 0.166 | 0.834 |
| Oxygen Saturation (%) | 75 (7) | 75 (7) | 76 (7) | 76 (7) | 76 (7) | | 0.942 | 0.754 |
| Hb (g/dl) | 15.1 (2.3) | 15.2 (2.6) | 15.0 (2.0) | 14.7 (2.0) | 15.7 (1.7) | | 0.471 | 0.687 |
| Extracardiac disease \(N\) (%) | None | 60 (65.2) | 39 (75.0) | 21 (52.5) | 15 (53.6) | 6 (50.0) | | \textbf{0.029} | 0.078 |
| Heterotaxy | 10 (10.8) | 5 (9.6) | 5 (12.5) | 0 (0) | 5 (41.7) | | 0.742 | \textbf{< 0.001} |
| Syndromic disease | 9 (9.8) | 4 (7.7) | 5 (12.5) | 5 (17.8) | 0 (0) | | 0.495 | 0.163 |
| Other severe chronic disease | 13 (14.1) | 4 (7.7) | 9 (22.5) | 8 (28.6) | 1 (8.3) | | 0.068 | \textbf{0.031} |
| Bilateral SVC \(N\) (%) | 11 (11.9) | 2 (3.8) | 9 (22.5) | 4 (14.3) | 5 (41.7) | | \textbf{0.008} | \textbf{0.001} |
| Previous surgery \(N\) (%) | None | 12 (13.0) | 7 (13.5) | 5 (12.5) | 0 (0) | 5 (41.7) | | \textbf{< 0.99} | \textbf{0.002} |
| Norwood-Blalock shunt | 11 (12.0) | 6 (11.5) | 5 (12.5) | 5 (17.8) | 0 (0) | | \textbf{> 0.99} | 0.277 |
| Norwood-Sano shunt | 24 (26.1) | 2 (3.8) | 22 (55.0) | 22 (78.6) | 0 (0) | | \textbf{< 0.001} | \textbf{< 0.001} |
| Norwood-hybrid | 1 (1.1) | 0 (0) | 1 (2.5) | 1 (3.6) | 0 (0) | | 0.435 | 0.315 |
| Systemic-pulmonary shunt | 34 (37.0) | 29 (56.0) | 5 (12.5) | 0 (0) | 5 (41.7) | | \textbf{< 0.001} | \textbf{< 0.001} |
| PA band | 8 (8.7) | 7 (13.5) | 1 (2.5) | 0 (0) | 1 (8.3) | | 0.132 | 0.252 |
| Other | 2 (2.2) | 1 (1.9) | 1 (2.5) | 0 (0) | 1 (8.3) | | \textbf{> 0.99} | 0.249 |
| Catheterization pre-BDCPC | Total \(N\) (%) | 73/87 (90.8%) | 38/49 (77.6%) | 35/38 (92.1) | 26/28 (92.9%) | 9/10 (90%) | | 0.083 | 0.182 |
| Interventional N (\%/mmHg) | | 11/73 (15.1%) | 3/38 (7.9%) | 8/35 (22.9%) | 7/26 (26.9%) | 1/9 (11.1%) | | 0.106 | 0.104 |
| Mean PAP (mmHg) | 14 (4) | 14 (3) | 14 (5) | 15 (5) | 13 (3) | | 0.311 | 0.932 |
| TP gradient (mmHg) | 7 (3) | 7 (3) | 7 (4) | 8 (4) | 6 (3) | | 0.294 | 0.879 |
| SVEDP (mmHg) | 9 (2) | 9 (2) | 9 (2) | 9 (2) | 8 (2) | | 0.248 | 0.113 |
| Nakata index (\%/mm\(^2\)) | 221 (115) | 251 (125) | 184 (94) | 162 (84) | 274 (83) | | \textbf{0.003} | 0.054 |
| Qp:Qs ratio | 1 (0.7) | 1 (0.6) | 1.1 (0.70) | 1.1 (0.8) | 1.2 (0.6) | | 0.721 | 0.469 |
| Volumetric EF (%) | 57 (9) | 61 (9) | 56 (8) | 55 (10) | 59 (9) | | \textbf{0.02} | \textbf{0.036} |
| Medication profile pre-BDCPC \(N\) (%) | None | 16 (17.4) | 9 (17.3) | 7 (17.5) | 1 (3.6) | 6 (50.0) | | \textbf{> 0.99} | \textbf{0.002} |
| Aspirin | 45 (48.9) | 25 (48.1) | 20 (50.0) | 19 (67.9) | 1 (8.3) | | \textbf{> 0.99} | \textbf{0.003} |
| Diuretics | 28 (30.4) | 13 (25.0) | 15 (37.5) | 13 (46.4) | 2 (16.7) | | 0.254 | 0.075 |
| Digoxin | 30 (32.6) | 14 (26.9) | 16 (40.0) | 13 (46.4) | 3 (25.0) | | 0.262 | 0.173 |
| ACE inhibitor | 14 (15.2) | 4 (7.7) | 10 (25.0) | 10 (35.7) | 0 (0) | | \textbf{0.038} | \textbf{0.001} |

Results are in mean (standard deviation) and \(N\) (%). Bold indicates significant values.

BDCPC bidirectional cavopulmonary connection, \(LV\) left ventricle, \(RV\) right ventricle, \(HLHS\) hypoplastic left heart syndrome, \(BSA\) body surface area, \(Hb\) hemoglobin, \(chrs\) chromosomic, \(SVC\) superior vena cava, \(PA\) pulmonary artery, \(PAP\) pulmonary artery pressure, \(TP\) transpulmonary pressure, \(SVEDP\) single ventricle end diastolic pressure, \(QP\) Pulmonary flow, \(QS\) Systemic flow, \(EF\) Ejection Fraction, \(ACE\) angiotensin conversion enzyme.

34 months [30;40] with an interval between BDCPC and Fontan procedures of 26 months [21;34]. One patient was lost to follow-up, and therefore included as censored data in the survival analysis.
Table 2  BDCPC: operative and post-operative data

| Variables                                      | Total (N=92) | LV group (N=52) | RV group (N=40) | HLHS group (N=28) | Non-HLHS RV group (N=12) | p value Comparison LV vs. RV | p value Comparison LV vs. HLHS vs non-HLHS RV |
|------------------------------------------------|--------------|-----------------|-----------------|-------------------|--------------------------|-----------------------------|-----------------------------------|
| **Cardiopulmonary bypass time**                |              |                 |                 |                   |                          | 0.163                       | 0.575                             |
| N (%)                                           | 85 (92.4)    | 47 (90.4)       | 38 (95.0)       | 26 (92.8)         | 12 (100)                 |                             |                                   |
| Time (min)                                      | 65 [42;92]   | 65 [45;101]     | 65 [42;87]      | 63 [40;95]        | 67 [49;83]               |                             |                                   |
| **Circulatory arrest time**                     |              |                 |                 |                   |                          | 0.287                       | 0.387                             |
| N (%)                                           | 39 (42.4)    | 25 (48.1)       | 14 (35.0)       | 9 (32.1)          | 5 (41.7)                 |                             |                                   |
| Time (min)                                      | 21 [16;31]   | 23 [16.5;35]    | 19 [14.5;22.5]  | 19 [14;24]        | 20 [15.5;21.5]           |                             |                                   |
| **Deep hypothermic circulatory arrest < 28 °C N (%)** |              |                 |                 |                   |                          |                             |                                   |
| Time (min)                                      | 39 (42.3)    | 19 (36.5)       | 20 (50.0)       | 13 (46.4)         | 7 (58.3)                 | 0.062                       | 0.339                             |
| **Additional surgical procedure N (%)**         |              |                 |                 |                   |                          |                             |                                   |
| None                                            | 29 (31.5)    | 16 (30.8)       | 13 (32.5)       | 8 (28.6)          | 5 (41.7)                 | > 0.99                      | 0.705                             |
| Atrioventricular valve repair                   | 8 (8.6)      | 5 (9.6)         | 3 (7.5)         | 2 (7.1)           | 1 (8.3)                  | > 0.99                      | 0.931                             |
| Pulmonary arterioplasty                         | 33 (35.8)    | 18 (34.6)       | 15 (37.5)       | 13 (46.4)         | 2 (16.7)                 | 0.828                       | 0.191                             |
| Aortic arch repair                              | 7 (7.6)      | 2 (3.8)         | 5 (12.5)        | 5 (17.9)          | 0 (0)                    | 0.233                       | 0.045                             |
| Atrial septectomy                               | 15 (16.3)    | 8 (15.4)        | 7 (17.5)        | 6 (21.4)          | 1 (8.3)                  | 0.746                       | 0.568                             |
| Other                                           | 25 (27.2)    | 17 (32.7)       | 8 (20.0)        | 5 (17.9)          | 3 (25.0)                 | 0.238                       | 0.358                             |
| **Peak post-op lactate levels (mmol/L)**        | 2.25 [1.6;3.4] | 2 [1.3;2.85]   | 2.8 [1.8;4.7]  | 3.0 [2.0;4.9]     | 1.8 [1.5;2.6]           | 0.068                       | 0.069                             |
| **Hospital length of stay (days)**              | 7 [6;9]      | 6 [5.9]         | 8 [6;10]        | 8.5 [6;15.5]      | 7.5 [6;8]                | 0.218                       | 0.127                             |
| **Post-op inhaled NO use N (%)**                | 15 (16.3)    | 8 (15.4)        | 7 (18.4)        | 7 (25.0)          | 0 (0)                    | 0.785                       | 0.141                             |
| **Duration of intubation (days)**               | 1 [0.5;3]    | 1 [0.5;3]       | 1 [0.5;2.8]     | 1 [0.5;3]         | 1 [0.6;1]                | 0.167                       | 0.065                             |
| **Complications prior to discharge N (%)**      |              |                 |                 |                   |                          |                             |                                   |
| none                                            | 58 (63.0)    | 34 (65.4)       | 24 (60)         | 17 (60.7)         | 7 (58.3)                 | 0.666                       | 0.859                             |
| respiratory                                     | 15 (16.3)    | 7 (13.5)        | 8 (20.5)        | 5 (17.9)          | 3 (25.0)                 | 0.411                       | 0.599                             |
| infectious                                      | 10 (10.9)    | 5 (9.6)         | 5 (12.8)        | 5 (17.9)          | 0 (0)                    | 0.742                       | 0.228                             |
| hemodynamic instability                         | 11 (12.0)    | 6 (11.5)        | 5 (12.8)        | 4 (14.3)          | 1 (8.3)                  | > 0.99                      | 0.859                             |
| gastrointestinal                                 | 5 (5.4)      | 1 (1.9)         | 4 (10.3)        | 4 (14.3)          | 0 (0)                    | 0.163                       | 0.445                             |
| death                                           | 1 (1.1)      | 1 (1.9)         | 0 (0)           | 0 (0)             | 0 (0)                    | > 0.99                      | 0.678                             |
| Creatinine at discharge (mg/dl)                 | 0.3 [0.2;0.4] | 0.3 [0.2;0.4]  | 0.4 [0.2;0.5]  | 0.3 [0.2;0.4]     | 0.4 [0.3;0.5]            | 0.588                       | 0.331                             |
| **Medication profile at discharge N (%)**       |              |                 |                 |                   |                          |                             |                                   |
| None                                            | 1 (10.9)     | 1 (1.9)         | 0 (0)           | 0 (0)             | 0 (0)                    | > 0.999                     | 0.672                             |
| Aspirin                                         | 71 (78.9)    | 41 (80.4)       | 34 (85.0)       | 25 (89.3)         | 9 (75.0)                 | 0.782                       | 0.469                             |
| Diuretics                                       | 78 (85.7)    | 41 (80.4)       | 37 (92.5)       | 27 (96.4)         | 10 (83.3)                | 0.248                       | 0.145                             |
| Digoxin                                         | 33 (36.2)    | 11 (21.6)       | 22 (55.5)       | 16 (57.1)         | 6 (50.0)                 | 0.002                       | 0.004                             |
| ACE inhibitor                                   | 36 (39.6)    | 18 (35.3)       | 18 (45.0)       | 12 (42.8)         | 6 (50.0)                 | 0.392                       | 0.587                             |
| PAH treatment                                   | 3 (3.3)      | 1 (1.9)         | 2 (5)           | 2 (7.1)           | 0 (0)                    | 0.580                       | 0.406                             |
| **Catheterization pre-Fontan**                  |              |                 |                 |                   |                          |                             |                                   |
| Total N (%)                                     | 64/70 (91.4) | 35/39 (89.7)    | 29/31 (93.5)    | 19/20 (95.0)      | 10/11 (90.9)             | 0.684                       | 0.776                             |
| Mean PAP (mmHg)                                 | 13 (2)       | 12 (2)          | 13 (2)          | 12 (2)            | 14 (2)                   | 0.761                       | 0.107                             |
| TP gradient (mmHg)                              | 5 (2)        | 5 (2)           | 4 (2)           | 4 (1)             | 5 (3)                    | 0.143                       | 0.137                             |
| SVEDP (mmHg)                                    | 10 (7)       | 11 (9)          | 9 (2)           | 9 (2)             | 9 (3)                    | 0.198                       | 0.441                             |
| Volumetric EF (%)                               | 57 (8)       | 59 (7)          | 54 (8)          | 53 (8)            | 55 (9)                   | 0.061                       | 0.169                             |

Results are in median [interquartile 1;3] or N (%). Bold indicates significant values.

BDCPC bidirectional cavopulmonary connection, LV left ventricle, RV right ventricle, HLHS hypoplastic left heart syndrome, NO nitric oxide, ACE angiotensin conversion enzyme, PAH pulmonary artery hypertension, EF ejection fraction.
dysfunction post-BDCPC (EF < 50% at hospital discharge). Major cardiac events were reported as follows:

- 6 patients had Fontan circulation failure or were not Fontan candidates
  1 patient had BDCPC takedown (detailed above), 1 patient had Fontan takedown (due to pulmonary vein stenosis), 2 patients were not candidates for Fontan procedure because of pulmonary artery hypoplasia, and 2 others were considered as “failing Fontan” (due to reduced EF and extracardiac conduit thrombosis in one patient, and severe AV regurgitation with cyanosis in the other patient). Four of these 6 patients experienced ventricular dysfunction post-BDCPC.
- 4 patients died: 1 after BDCPC (detailed above) and 3 after Fontan (all with HLHS, 1 from RSV bronchiolitis, 1 from Pseudomonas aeruginosa pneumonia and 1 from acidosis due to lower extremity ischemia). All patients experienced ventricular dysfunction post-BDCPC.
- 3 patients had heart transplantation at 14 [12;16] years old; 11 [9;13.5] years post-Fontan, all were in the RV group and none had ventricular dysfunction post-BDCPC.

Figures 2 and 3 show major cardiac event survival curves: RV patients had a higher hazard ratio (HR) (1.63; 95% CI (0.52, 5.15)) than LV patients, with 35% vs. 88% freedom from major cardiac event at 20 years, respectively. This difference was not statistically significant (p = 0.40). Patients with post-BDCPC ventricular dysfunction (discharge EF < 50%) had a higher HR (HR 3.89; 95% CI 1.04–14.52) than those with a discharge EF ≥ 50%, with 75% vs. 92% freedom from major cardiac events at 15 years, respectively, (p = 0.04).

### Table 3 Mean EF evolution according to ventricular morphology in the entire cohort

| Time of analysis | Total | LV group | RV group | HLHS group | Non-HLHS RV group |
|------------------|-------|----------|----------|------------|-------------------|
| Pre-BDCPC        | 59 ± 6% (N=92) | 61 ± 5% (N=52) | 56 ± 6% (N=40) | 55 ± 7% (N=28) | 58 ± 3% (N=12) |
| Hospital discharge | 55 ± 7% (N=92) | 59 ± 6% (N=52) | 50 ± 7% (N=40) | 49 ± 7% (N=28) | 54 ± 6% (N=12) |
| 1–3 months post-BDCPC | 57 ± 6% (N=42) | 59 ± 4% (N=21) | 52 ± 5% (N=21) | 51 ± 5% (N=17) | 56 ± 3% (N=4) |
| 6–12 months post-BDCPC | 56 ± 7% (N=66) | 59 ± 5% (N=33) | 51 ± 7% (N=33) | 50 ± 7% (N=26) | 56 ± 6% (N=7) |
| Pre-Fontan        | 58 ± 5% (N=69) | 60 ± 4% (N=39) | 54 ± 4% (N=30) | 53 ± 3% (N=19) | 56 ± 6% (N=10) |

Table 3 Mean EF evolution according to ventricular morphology in the entire cohort

Results are in mean ± standard deviation. Bold indicates significant values

**BDCPC** bidirectional cavopulmonary connection, **EF** ejection fraction, **LV** left ventricle, **RV** right ventricle, **HLHS** hypoplastic left heart syndrome

### Table 4 Mean EF evolution according to ventricular morphology for patients with EF≥50% at baseline

| Time of analysis | Total | LV group | RV group | HLHS group | Non-HLHS RV group |
|------------------|-------|----------|----------|------------|-------------------|
| Pre-BDCPC        | 60 ± 4% (N=81) | 61 ± 4% (N=49) | 58 ± 3% (N=32) | 59 ± 4% (N=20) | 58 ± 3% (N=12) |
| Hospital discharge | 56 ± 7% (N=81) | 60 ± 4% (N=49) | 51 ± 7% (N=32) | 49 ± 7% (N=20) | 54 ± 6% (N=12) |
| 1–3 months post-BDCPC | 56 ± 5% (N=33) | 59 ± 4% (N=18) | 52 ± 4% (N=15) | 51 ± 4% (N=11) | 56 ± 3% (N=4) |
| 6–12 months post-BDCPC | 56 ± 6% (N=56) | 59 ± 5% (N=31) | 52 ± 7% (N=25) | 50 ± 7% (N=18) | 56 ± 6% (N=7) |
| Pre-Fontan        | 58 ± 5% (N=64) | 60 ± 4% (N=39) | 55 ± 4% (N=25) | 54 ± 2% (N=14) | 56 ± 6% (N=11) |

Table 4 Mean EF evolution according to ventricular morphology for patients with EF≥50% at baseline

Results are in mean ± standard deviation. Bold indicates significant values

**BDCPC** bidirectional cavopulmonary connection, **EF** ejection fraction, **LV** left ventricle, **RV** right ventricle, **HLHS** hypoplastic left heart syndrome
Risk Factor Analysis

The HR for major cardiac events in patients with pre-BDCPC ventricular dysfunction (pre-BDCPC EF < 50%) is 7.8 times higher than for patients with pre-BDCPC EF of ≥ 50% (p < 0.001). The HR for major cardiac event in patients with post-BDCPC ventricular dysfunction (discharge EF < 50%, adjusted on pre-BDCPC EF) is 3.9 times higher than patients with a discharge EF of ≥ 50% (p = 0.04). Every 5% decrease in EF from baseline to discharge was associated with a 1.63 HR. This result approached statistical significance (p = 0.052). Younger age at BDCPC (<4 months old) and associated extracardiac disease were also associated with a higher HR of a major cardiac event. Finally, we found no significant association between Nakata index, cardiopulmonary bypass time, or ventricular morphology with major cardiac events (Table 5).

Discussion

We conducted the first functional SV study investigating the period between BDCPC and Fontan procedures using EF evaluation. Our first goal was to define whether the BDCPC impacted the SV function according to ventricular morphology. We found a decrease in the mean EF in the RV group after BDCPC, especially in the HLHS subset. This 9% drop in the HLHS group at hospital discharge was clinically relevant, and these patients did not completely recover function before Fontan. In contrast, the mean EF in the LV group remained stable over time.

Several studies have shown a decrease in single RV contractility at different stages of palliation with standard echo parameters [13], 2D strain [18–20], 3D real-time echo [21], or cardiac MRI [22]. Kutty et al. showed an 8% decrease in EF with 3D real-time echo (46 ± 5% before and 38 ± 4% after BDCPC) in patients with HLHS, which is comparable to our results [21].

The etiology of decreased contractility post-BDCPC in the patient with functional single RV remains unclear. The role of loading changes, including decreased preload [21] and chronic pressure overload [23] on an inadequate ventricle, is the most frequent explanation. Embryologic, histologic, and anatomic differences between the RV and LV seem to impact response to load variation, despite RV remodeling [23]. Diffuse fibrosis on cardiac MRI is reported after Fontan in patients with RV morphology compared to LV [24]. 2D strain studies in single
RV patients showed that changes in circumferential contraction over time: decreased circumferential stain after stage I [18, 25] and reduced longitudinal to circumferential ratio after stage III [19], mimic changes in LV contraction. This may result in lower coronary flow reserve [26] and a potentially greater influence of ischemia due to recurrent surgeries.

Furthermore, mechanical dyssynchrony, if not the major factor explaining early cardiac dysfunction, may impact RV function in older patients [27, 28]. Finally, tricuspid regurgitation due to progressive RV dilatation contributes to worsening of ventricular function [29]. Consistently in our study, AV valve dysfunction was more common in the RV group than in the LV group.

Why does ventricular function become worse in the HLHS subgroup after stage II palliation? In addition to the RV morphology, some other negative factors have been previously linked to HLHS anatomy: complex stage I palliation with high post-operative morbidity [30], younger age at stage II [31], recurrent aortic arch obstruction [32], and pulmonary artery hypoplasia [33]. In our study, the HLHS group had all of these factors which potentially explained its great vulnerability.

Our second objective was to determine if the decrease in ventricular function after BDCPC was associated with poor long-term prognosis. We found that EF < 50% at BDCPC discharge was strongly correlated with a higher risk (3.9×) for major cardiac events including Fontan circulation failure, heart transplantation, or death. Similarly, the risk of a major cardiac event was proportional to the post-BDCPC EF decrease.

Retrospective studies of patients with functional SV with long-term follow-up data reported other risk factors that negatively impact prognosis including arrhythmia, atrioventricular valve regurgitation, and prolonged pleural effusion drainage [6, 34]. Two large consortium studies (Single Ventricle Reconstruction Trial from North America [4, 5, 35] and the Australian and New Zealand Stage III Registry [8]) followed patients with functional SV physiology over time. In these studies, atrioventricular valve regurgitation and heterotaxy were predictors of mortality [8]. But source of pulmonary blood flow (modified Blalock-Taussig shunt versus RV to the pulmonary artery conduit (Sano shunt)) at stage I did not change long-term prognosis [4, 5, 35].

Several studies have correlated SV function to prognosis: qualitative SV dysfunction pre-Norwood [36], lower
longitudinal and circumferential strain in the interstage period [37], and smaller tissue Doppler annular displacement pre-Stage II [38]. These issues have been associated with a shorter transplant-free survival in patients with HLHS.

Similar to other reports [6, 39], our study also did not demonstrate a correlation between SV morphology and long-term prognosis. However, HLHS anatomy is known to be associated with a more poor long-term prognosis [8, 40] and the follow-up of this group is still limited.

HLHS anatomy in our study was strongly associated with post-BDCPC ventricular dysfunction which was related to poor long-term prognosis. Despite improvements in surgical techniques and anesthesia management, medical treatment of RV failure remains ineffective [41, 42] and heart transplantation remains the definitive therapy for end-stage RV failure. Preservation of RV function should be a major goal at each step of palliation for patients with HLHS. Hopefully, novel therapies may alter this natural history.

**Limitations**

Mayo Clinic is a tertiary care referral center for congenital heart disease. This study is limited by the number of patients who had follow-up echocardiograms at our institution.

Assessing functionally SV function remains an unresolved issue especially for RV type morphology. Since this was a retrospective study, biplane pyramidal EF, strain analysis, 3D echocardiography, and cardiac MRI were not available for all patients. We also needed imaging data pre- and post-operative BDCPC to accurately assess RV function.
post-stage II. For now, only standard 2D echocardiography is considered as appropriate imaging for routine surveillance post-stage II [43]; hence, reliance on 2D echocardiography until cardiac MRI pre- and post-stage II becomes standard of care. Furthermore, we wanted to use one common parameter for LV and RV morphology in order to compare the evolution of ventricular function in the LV and RV groups with the same contractility parameter (EF) and therefore similar limitations regarding dependency on load conditions. We found in fact that the EF decline was much worse in the RV group (especially for patients with HLHS) than in the LV group. Visually estimated EF is a subjective evaluation of ventricular contractility but its reliability to objective parameters (automated biplane EF for LV and MRI for RV) have been reported [14, 15] and in our study, volumetric EF measurements from catheterization at pre-BDCPC and pre-Fontan time were similar and correlated to the same time-point echocardiographic values. Finally, our 5% decrease in EF used in the risk factor analysis may be within the margin of error of the estimated EF.

Major cardiac event survival curves according to SV morphology showed no difference until 10 years post-stage II follow-up and then a separation of the two curves with big steps down for the RV group but without significant difference between groups. Small number of patients with long-term follow-up may be confounding factor and potentially explains why the difference between groups was not statistically significant.

A prospective study is critically needed given these limitations.

Conclusion

Compared to patients with LV morphology, patients with RV morphology, especially those with HLHS, are at greater risk of post-BDCPC ventricular dysfunction. This dysfunction is associated with long-term major cardiac events. Strategies to maintain ventricular function as normal as possible at BDCPC could be reasonably expected to contribute to improved long-term prognosis, especially for patients with HLHS. These results should be confirmed by a multicenter prospective study to minimize inclusion bias. Preserving ventricular function remains a therapeutic challenge for the care team. New therapeutic approaches are needed in this regard.

Conflict of interest All the authors have declared no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Herrmann JL, Brown JW (2019) The superior cavopulmonary connection: history and current perspectives. World J Pediatr Congenit Heart Surg 10:216–222. https://doi.org/10.1016/j.wjchs.2019.01.017
2. Kim AS, Witzenburg CM, Conaway M et al (2019) Trajectory of right ventricular indices is an early predictor of outcomes in hypoplastic left heart syndrome. Congenit Heart Dis. https://doi.org/10.1111/chd.12834
3. Simsic JM, Phelps C, Kirchner K et al (2018) Interstage outcomes in single ventricle patients undergoing hybrid stage I palliation. Congenit Heart Dis 13:757–763. https://doi.org/10.1111/chd.12649
4. Tabbutt S, Ghanayem N, Ravishankar C et al (2012) Risk factors for hospital morbidity and mortality after the Norwood procedure: a report from the pediatric heart network single ventricle reconstruction trial. J Thorac Cardiovasc Surg 144:882–895. https://doi.org/10.1016/j.jtcvs.2012.05.019
5. Ghanayem NS, Allen KR, Tabbutt S et al (2012) Interstage mortality after the Norwood procedure: results of the multicenter single ventricle reconstruction trial. J Thorac Cardiovasc Surg 144:896–906. https://doi.org/10.1016/j.jtcvs.2012.05.020
6. Pundi KN, Johnson JN, Dearani JA et al (2015) 40-Year follow-up after the Fontan operation: long-term outcomes of 1,052 patients. J Am Coll Cardiol 66:1700–1710. https://doi.org/10.1016/j.jacc.2015.07.065
7. Khairy P, Fernandes SM, Mayer JE et al (2008) Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation 117:85–92. https://doi.org/10.1161/CIRCULATIONAHA.107.738559
8. d’Udekem Y, Iyengar AJ, Galati JC et al (2014) Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation 130:S32–38. https://doi.org/10.1161/CIRCULATIONAHA.113.007764
9. Eckhauser A, Pasquali SK, Ravishankar C et al (2018) Variation in care for infants undergoing the Stage II palliation for hypoplastic left heart syndrome. Cardiol Young 28:1109–1115. https://doi.org/10.1017/S1047951118000999
10. Di Molfetta A, Iacobelli R, Guccione P et al (2017) Evolution of ventricular energetics in the different stages of palliation of hypoplastic left heart syndrome: a retrospective clinical study. Pediatr Cardiol 38:1613–1619. https://doi.org/10.1007/s00246-017-1704-8
11. Arnold RR, Loukanov T, Gorenflo M (2014) Hypoplastic left heart syndrome-unresolved issues. Front Pediatr 2:125. https://doi.org/10.3389/fped.2014.00125
12. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet Lond Engl 1:307–310
13. Mahle WT, Coon PD, Wernovsky G, Rychik J (2001) Quantitative echocardiographic assessment of the performance of the functionally single right ventricle after the Fontan operation.
14. Abazid RM, Abouhamr SI, Smettei OA et al (2018) Visual versus fully automated assessment of left ventricular ejection fraction. Avicenna J Med 8:41–45. https://doi.org/10.4103/ajm.AJM_209_17
15. Schneider M, Ran H, Aschauer S et al (2019) Visual assessment of right ventricular function by echocardiography: how good are we? Int J Cardiovasc Imaging 35:2001–2008. https://doi.org/10.1007/s10554-019-01653-2
16. Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420–428. https://doi.org/10.1037/0033-2909.86.2.420
17. Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163. https://doi.org/10.1016/j.jcim.2016.02.012
18. Kaneko S, Khoo NS, Smallhorn JF, Tham EB (2012) Single right ventricles have impaired systolic and diastolic function compared to those of left ventricular morphology. J Am Soc Echocardiogr 25:1222–1230. https://doi.org/10.1016/j.echo.2012.08.005
19. Tham EB, Smallhorn JF, Kaneko S et al (2014) Insights into the evolution of myocardial dysfunction in the functionally single right ventricle between staged palliations using speckle-tracking echocardiography. J Am Soc Echocardiogr 27:314–322. https://doi.org/10.1016/j.echo.2013.11.012
20. Suntratonpipat S, Khoo NS, Colen T et al (2017) Impaired single right ventricular function compared to single left ventricles during the early stages of palliation: a longitudinal study. J Am Soc Echocardiogr 30:468–477. https://doi.org/10.1016/j.echo.2017.01.001
21. Kutty S, Graney BA, Khoo NS et al (2012) Serial assessment of right ventricular volume and function in surgically palliated hypoplastic left heart syndrome using real-time transthoracic three-dimensional echocardiography. J Am Soc Echocardiogr 25:682–689. https://doi.org/10.1016/j.echo.2012.02.008
22. Sundareswaran KS, Kanter KR, Kitajima HD et al (2006) Impaired power output and cardiac index with hypoplastic left heart syndrome: a magnetic resonance imaging study. Ann Thorac Surg 82:1267–1275. https://doi.org/10.1016/j.athoracsur.2006.05.020; discussion 1275–1277
23. Si M-S, Ohye RG (2017) Stem cell therapy for the systemic right ventricle. Expert Rev Cardiovasc Ther 15:813–823. https://doi.org/10.1080/14779072.2017.1379898
24. Kato A, Riesenkampff E, Yim D et al (2017) Pediatric Fontan patients are at risk for myocardial fibrotic remodeling and dysfunction. Int J Cardiol 240:172–177. https://doi.org/10.1016/j.ijcard.2017.04.073
25. Khoo NS, Smallhorn JF, Kaneko S et al (2011) Novel insights into RV adaptation and function in hypoplastic left heart syndrome between the first 2 stages of surgical palliation. JACC Cardiovasc Imaging 4:128–137. https://doi.org/10.1016/j.jcmg.2010.09.022
26. Hauser M, Bengel FM, Hager A et al (2003) Impaired myocardial blood flow and coronary flow reserve of the anatomical right systemic ventricle in patients with congenitally corrected transposition of the great arteries. Heart Br Card Soc 89:1231–1235. https://doi.org/10.1136/hrt.89.10.1231
27. Zaidi SJ, Penk J, Cui VW, Roberson DA (2019) Right ventricular mechanical dysynchrony in hypoplastic left heart syndrome: correlation with systolic function and QRS duration. Pediatr Cardiol 40:934–942. https://doi.org/10.1007/s00246-019-02091-6
28. Friedberg MK, Silverman NH, Dubin AM, Rosenthal DN (2007) Right ventricular mechanical dysynchrony in children with hypoplastic left heart syndrome. J Am Soc Echocardiogr 20:1073–1079. https://doi.org/10.1016/j.echo.2007.02.015
29. Ghelani SJ, Colan SD, Azcue N et al (2018) Impact of ventricular morphology on fiber stress and strain in Fontan patients. Circ Cardiovasc Imaging 11:e006738. https://doi.org/10.1161/CIRCMAGING.117.006738
30. Hornik CP, He X, Jacobs JP et al (2011) Complications after the Norwood operation: an analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database. Ann Thorac Surg 92:1734–1740. https://doi.org/10.1016/j.athoracsur.2011.05.100
31. Cnota JF, Allen KR, Colan S et al (2013) Superior cavo-pulmonary anastomosis timing and outcomes in infants with single ventricle. J Thorac Cardiovasc Surg 145:1288–1296. https://doi.org/10.1016/j.jtcvs.2012.07.069
32. Gaynor JW, Mahle WT, Cohen MI et al (2002) Risk factors for mortality after the Norwood procedure. Eur J Cardio-Thorac Surg 22:82–89. https://doi.org/10.1016/s1010-7940(02)00198-7
33. Aiyagari R, Rhodes JF, Shradar P et al (2014) Impact of pre-stage II hemodynamics and pulmonary artery anatomy on 12-month outcomes in the Pediatric Heart Network Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg 148:1467–1474. https://doi.org/10.1016/j.jtcvs.2013.10.057
34. Wilson TG, Shi WY, Iyengar AJ et al (2017) Twenty-five year outcomes of the lateral tunnel Fontan procedure. Semin Thorac Cardiovasc Surg Cardiovasc 29:347–353. https://doi.org/10.1053/j.semcvs.2017.06.002
35. Frommelt PC, Hu C, Trachtenberg F et al (2019) Impact of initial shunt type on echocardiographic indices in children after single right ventricle palliations. Circ Cardiovasc Imaging 12:e007865. https://doi.org/10.1161/CIRCIMAGING.118.007865
36. Altmann K, Pritzl BF, Solowiejczyk DE et al (2000) Two-dimensional echocardiographic assessment of right ventricular function as a predictor of outcome in hypoplastic left heart syndrome. Am J Cardiol 86:964–968. https://doi.org/10.1016/s0002-9149(00)01131-0
37. Colquitt JL, Loar RW, Morris SA et al (2019) Serial strain analysis identifies hypoplastic left heart syndrome infants at risk for cardiac morbidity and mortality: a pilot study. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 32:643–650. https://doi.org/10.1016/j.echo.2019.01.006
38. Penk JS, Zaidi SJH, Lefaiver CA et al (2018) Tissue motion annular displacement predicts mortality/transfer after the bidirectional Glenn. World J Pediatr Congenit Heart Surg 9:171–176. https://doi.org/10.10117/2150135117742650
39. Alsoûâû B, Gillespie S, Kim D et al (2016) The impact of dominant ventricular morphology on palliation outcomes of single ventricle anomalies. Ann Thorac Surg 102:593–601. https://doi.org/10.1016/j.atvhscr.2016.04.054
40. Iyengar AJ, Winlaw DS, Galati JC et al (2014) The extracardiac conduit Fontan procedure in Australia and New Zealand: hypoplastic left heart syndrome predicts worse early and late outcomes. Eur J Cardio-Thorac Surg 46:465–473. https://doi.org/10.1093/ ejcts/ezu015; discussion 473
41. Josephson CB, Howlett JG, Jackson SD et al (2006) A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol 22:769–772. https://doi.org/10.1016/s0828-282x(06)70293-8
42. Dore A, Houde C, Chan K-L et al (2005) Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricle: a multicenter, randomized, placebo-controlled clinical trial. Circulation 112:2411–2416. https://doi.org/10.1161/CIRCULATIONAHA.105.543470
43. Writing Group, Sachdeva R, Valente AM et al (2020) J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2019.10.002

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.